Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-10-13 10:21Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its self-developed antibody-drug conjugate, SHR-A2102, targeting Nectin-4, which is associated with tumor progression and poor prognosis [1] Group 1: Company Developments - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Hengrui Medicine Co., Ltd. have been granted the clinical trial approval for SHR-A2102 [1] - SHR-A2102 is an antibody-drug conjugate (ADC) with a payload of topoisomerase I inhibitor (TOP1i) [1] Group 2: Industry Context - Nectin-4 is highly expressed in tumors, correlating with tumor development and adverse prognosis, highlighting the potential significance of SHR-A2102 in cancer treatment [1]